Company intelligence / Profile preview

PathomIQ

Cupertino, California, United States

Ownership: Private
Development stage: Other

Overview

PathomIQ's flagship platform PATHOMIQ_PRAD has been clinically validated at multiple medical institutions and with pharmaceutical partners, showing high prognostic accuracy in prostate cancer—including outperforming some existing markers for identifying high-risk patients post-surgery and informing metastasis risk in non-metastatic castration-resistant prostate cancer. Six studies have been completed or are ongoing, and the platform is being commercially deployed via a partnership with Myriad Genetics for a clinical prostate cancer test in 2025[1][2][5].

Therapeutic areas: Oncology
Industry: Pathology

Partnerships

Myriad Genetics (exclusive U.S. license for prostate cancer; commercial launch partner)[1][2][3]Janssen (collaboration to evaluate AI prognostic stratification in non-metastatic castration-resistant prostate cancer)[5]

Beyond the preview

Go deeper on PathomIQ.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PathomIQ.

Explore the full profile